Amicus Q2 rev $94.5M (+17% YoY); raises Galafold guidance to 14-18% growth; CFO Quimi to retire

AMICUS THERAPEUTICS, INC.

2023-Q2 EPS reported -$0.33 revenue$180,773,000

Q2 2023 total revenue $94.5M (+17% YoY at CER); net loss $43.2M ($0.15/sh), improved from $62.2M loss YoY.
Full-year Galafold revenue growth guidance raised to 14-18% at CER; non-GAAP operating expense guidance cut to $330M-$350M.
Company on track for non-GAAP profitability in H2 2023; expects U.S. and U.K. approvals of AT-GAA (Pombiliti+Opfolda) in Q3 2023.
CEO Quimi to retire; CFO role search underway with identified candidates; she will stay until successor appointed.
European launch of Pombiliti+Opfolda initiated in Germany; reimbursement discussions in additional EU countries ongoing.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Daphne Quimi

Chief Financial Officer

AMICUS THERAPEUTICS, INC.

Filed: August 8, 2023, 7:59 PM ET

The Company announced today that Daphne Quimi, the Company’s Chief Financial Officer, notified the Company on August 3, 2023 that she intends to retire before the end of 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daphne Quimi departed as Chief Financial Officer at AMICUS THERAPEUTICS, INC..

Action: intends to retire
Role: Chief Financial Officer

Exact text from the filing

The Company announced today that Daphne Quimi, the Company’s Chief Financial Officer, notified the Company on August 3, 2023 that she intends to retire before the end of 2023.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-23-088576

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.